EETs/sEH in diabetes and obesity-induced cardiovascular diseases

Prostaglandins and Other Lipid Mediators

Volumn 125, Issue , 2016, Pages 80-89

  Huang, Hui ^a,b   Weng, Jing ^c   Wang, Mong Heng ^c  

^a Key Laboratory of Cardiac Electrophysiology and Arrhythmia in Guangdong Province   (China)

^b SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Cytochrome P450; Diabetes; Eicosanoids; Obesity; Soluble epoxide hydrolase

Indexed keywords

CYTOCHROME P450; EPOXIDE HYDROLASE; EPOXYICOSATRIENOIC ACID; UNSPECIFIC MONOOXYGENASE; DIHOMO GAMMA LINOLENIC ACID;

BIOCHEMISTRY; CARDIOVASCULAR DISEASE; DIABETIC CARDIOMYOPATHY; DIABETOGENESIS; ENDOTHELIAL DYSFUNCTION; FATTY ACID SYNTHESIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; CARDIOVASCULAR DISEASES; CHEMISTRY; COMPLICATION; DIABETES MELLITUS; ENZYMOLOGY; METABOLISM; SOLUBILITY;

8,11,14-EICOSATRIENOIC ACID; ANIMALS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; EPOXIDE HYDROLASES; HUMANS; OBESITY; SOLUBILITY;

EID: 84970028145     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2016.05.004     Document Type: Review

References (82)

1. [1] Shaw, J.E., Sicree, R.A., Zimmet, P.Z., Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 87 (2010), 4–14.
2. [2] Yoon, J.W., Jun, H.S., Autoimmune destruction of pancreatic beta cells. Am. J. Ther. 12 (2005), 580–591.
3. [3] Cnop, M., Welsh, N., Jonas, J.C., et al. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 54 (2005), S97–107.
4. [4] Eizirik, D.L., Colli, M.L., Ortis, F., The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat. Rev. Endocrinol. 5 (2009), 219–226.
5. [5] WHO, Obesity and overweight: fact sheet World Health Organisation, (2015).
6. [6] Giacco, F., Brownlee, M., Oxidative stress and diabetic complications. Circ. Res. 107 (2010), 1058–1070.
7. [7] Garcia, C., Feve, B., Ferre, P., et al. Diabetes and inflammation: fundamental aspects and clinical implications. Diabetes Metab. 36 (2010), 327–338.
8. [8] Simpson, A.E., The cytochrome P450 4 (CYP4) family. Gen. Pharmacol. 28 (1997), 351–359.
9. [9] Poulos, T.L., Heme enzyme structure and function. Chem. Rev. 114 (2014), 3919–3962.
10. [10] Laniado-Schwartzman, M., Abraham, N.G., The renal cytochrome P450 arachidonic acid system. Pediatr. Nephrol. 6 (1992), 490–498.
11. [11] White, R.E., The involvement of free radicals in the mechanisms of monooxygenases. Pharmacol. Ther. 49 (1991), 21–42.
12. [12] Taniguchi, H., Imai, Y., Sato, R., Role of the electron transfer system in microsomal drug monooxygenase reaction catalyzed by cytochrome P-450. Arch. Biochem. Biophys. 232 (1984), 585–596.
13. [13] Strobel, H.W., Fang, W.F., Takazawa, R.S., et al. Cytochromes P-450 and the activation and inactivation of mutagens and carcinogens. Basic Life Sci. 39 (1986), 61–71.
14. [14] Nadler, S.G., Strobel, H.W., Identification and characterization of an NADPH-cytochrome P450 reductase derived peptide involved in binding to cytochrome P450. Arch. Biochem. Biophys. 290 (1991), 277–284.
15. [15] Black, S.D., Coon, M.J., P-450 cytochromes: structure and function. Adv. Enzymol. Relat. Areas Mol. Biol. 60 (1987), 35–87.
16. [16] Roman, R.J., P450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 82 (2002), 131–185.
17. [17] Schwartzman, M.L., Abraham, N.G., Carroll, M.A., et al. Regulation of arachidonic acid metabolism by cytochrome P450 in rabbit kidney. Biochem. J. 238 (1986), 283–290.
18. [18] Hoopes, S.L., Garcia, V., Edin, M.L., et al. Vascular actions of 20-HETE. Prostaglandins Other Lipid Mediat. 126 (2015), 9–16.
19. [19] Capdevila, J.H., Shouzou, W., Yan, J., et al. Cytochrome P450 arachidonic acid epoxygenase: regulatory control of the renal epoxygenase by dietary salt loading. J. Biol. Chem. 267 (1992), 21720–21726.
20. [20] Oliw, E.H., Oxygenation of polyunsaturated fatty acids by cytochrome P450 monooxygenases. Prog. Lipid Res. 33 (1994), 329–354.
21. [21] Karara, A., Makita, K., Jacobson, H.R., et al. Molecular cloning, expression and enzymatic characterization of the rat kidney cytochrome P450 arachidonic acid epoxygenase. J. Biol. Chem. 268 (1993), 13565–13570.
22. [22] Holla, V.R., Makita, K., Zaphiropoulos, P.G., et al. The kidney cytochrome P-450 2C23 arachidonic acid epoxygenase is upregulated during dietary salt loading. J. Clin. Invest. 104 (1999), 751–760.
23. [23] Ma, J., Qu, W., Scarborough, P.E., et al. Molecular cloning, enzymatic characterization, developmental expression, and cellular localization of a mouse cytochrome P450 highly expressed in kidney. J. Biol. Chem. 274 (1999), 17777–17788.
24. [24] Wu, S., Moomaw, C.R., Tomer, K.B., et al. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J. Biol. Chem. 271 (1996), 3460–3468.
25. [25] Shahabi, P., Siest, G., Meyer, U.A., et al. Human cytochrome P450 epoxygenases: variability in expression and role in inflammation-related disorders. Pharmacol. Ther. 144 (2014), 134–161.
26. [26] Daikh, B.E., Lasker, J.M., Raucy, J.L., et al. Regio- and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9. J. Pharmacol. Exp. Ther. 271 (1994), 1427–1433.
27. [27] Zeldin, D.C., DuBois, R.N., Falck, J.R., et al. Molecular cloning, expression and characterization of an endogenous human cytochrome P450 arachidonic acid epoxygenase isoform. Arch. Biochem. Biophys. 322 (1995), 76–86.
28. [28] Fleming, I., The pharmacology of the cytochrome P450 epoxygenase/soluble epoxide hydrolase axis in the vasculature and cardiovascular disease. Pharmacol. Rev. 66 (2014), 1106–1140.
29. [29] Yu, Z., Xu, F., Huse, L.M., et al. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ. Res. 87 (2000), 992–998.
30. [30] Imig, J.D., Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am. J. Physiol. 289 (2005), F496–F503.
31. [31] Imig, J.D., Eicosanoid regulation of the renal vasculature. Am. J. Physiol. 279 (2000), F965–F981.
32. [32] Oltman, C.L., Weintraub, N.L., VanRollins, M., et al. Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation. Circ. Res. 83 (1998), 932–939.
33. [33] Larsen, B.T., Miura, H., Hatoum, O.A., et al. Epoxyeicosatrienoic and dihydroxyeicosatrienoic acids dilate human coronary arterioles via BK(Ca) channels: implications for soluble epoxide hydrolase inhibition. Am. J. Physiol. 290 (2006), H491–H499.
34. [34] Hercule, H.C., Schunck, W.H., Gross, V., et al. Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice. Arterioscler. Thromb. Vasc. Biol. 29 (2009), 54–60.
35. [35] Imig, J.D., Zhao, X., Capdevila, J.H., et al. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39 (2002), 690–694.
36. [36] Jones, P.D., Tsai, H.J., Do, Z.N., et al. Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase. Bioorg. Med. Chem. Lett. 16 (2006), 5212–5216.
37. [37] Huang, H., Morisseau, C., Wang, J., et al. Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats. Am. J. Physiol. 293 (2007), F342–F349.
38. [38] Guglielmino, K., Jackson, K., Harris, T.R., et al. Pharmacological inhibition of soluble epoxide hydrolase provides cardioprotection in hyperglycemic rats. Am. J. Physiol. 303 (2012), H853–H862.
39. [39] Luo, P., Chang, H.H., Zhou, Y., et al. Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis. J. Pharmacol. Exp. Ther. 334 (2010), 430–438.
40. [40] Manhiani, M., Quigley, J.E., Knight, S.F., et al. Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am. J. Physiol. 297 (2009), F740–8.
41. [41] Elmarakby, A.A., Faulkner, J., Al-Shabrawey, M., et al. Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced type 1 diabetes. Am. J. Physiol. 301 (2011), R1307–R1317.
42. [42] Parrish, A.R., Chen, G., Burghardt, R.C., et al. Attenuation of cisplatin nephrotoxicity by inhibition of soluble epoxide hydrolase. Cell Biol. Toxicol. 25 (2009), 217–225.
43. [43] Henquin, J.C., Regulation of insulin secretion: a matter of phase control and amplitude modulation. Diabetologia 52 (2009), 739–751.
44. [44] Henquin, J.C., Pathways in beta-cell stimulus-secretion coupling as targets for therapeutic insulin secretagogues. Diabetes 53:Suppl 3 (2004), S48–S58.
45. [45] McDaniel, M.L., Kwon, G., Hill, J.R., et al. Cytokines and nitric oxide in islet inflammation and diabetes. Proc. Soc. Exp. Biol. Med. 211 (1996), 24–32.
46. [46] Henquin, J.C., Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 49 (2000), 1751–1760.
47. [47] Falck, J.R., Manna, S., Moltz, J., et al. Epoxyeicosatrienoic acids stimulate glucagon and insulin release from isolated rat pancreatic islets. Biochem. Biophys. Res. Commun. 114 (1983), 743–749.
48. [48] Zeldin, D.C., Foley, J., Boyle, J.E., et al. Predominant expression of an arachidonate epoxygenase in islets of Langerhans cells in human and rat pancreas. Endocrinology 138 (1997), 1338–1346.
49. [49] Imig, J.D., Hammock, B.D., Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat. Rev. Drug Discov. 8 (2009), 794–805.
50. [50] Lee, C.R., Imig, J.D., Edin, M.L., et al. Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J. 24 (2010), 3770–3781.
51. [51] Mustafa, S., Sharma, V., McNeill, J.H., Insulin resistance and endothelial dysfunction: are epoxyeicosatrienoic acids the link. Exp. Clin. Cardiol. 14 (2009), e41–e50.
52. [52] Zhang, C.Y., Baffy, G., Perret, P., et al. Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. Cell 105 (2001), 745–755.
53. [53] Chen, L., Fan, C., Zhang, Y., et al. Beneficial effects of inhibition of soluble epoxide hydrolase on glucose homeostasis and islet damage in a streptozotocin-induced diabetic mouse model. Prostaglandins Other Lipid Mediat. 104 (2013), 42–48.
54. [54] Enayetallah, A.E., French, R.A., Barber, M., et al. Cell-specific subcellular localization of soluble epoxide hydrolase in human tissues. J. Histochem. Cytochem. 54 (2006), 329–335.
55. [55] Barshes, N.R., Wyllie, S., Goss, J.A., Inflammation-mediated dysfunction and apoptosis in pancreatic islet transplantation: implications for intrahepatic grafts. J. Leukoc. Biol. 77 (2005), 587–597.
56. [56] Bleich, D., Chen, S., Gu, J.L., et al. The role of 12-lipoxygenase in pancreatic—cells (Review). Int. J. Mol. Med. 1 (1998), 265–272.
57. [57] Boden, G., Obesity insulin resistance and free fatty acids. Curr. Opin. Endocrinol. Diabetes Obes. 18 (2011), 139–143.
58. [58] Eckardt, K., Taube, A., Eckel, J., Obesity-associated insulin resistance in skeletal muscle: role of lipid accumulation and physical inactivity. Rev. Endocr. Metab. Disord. 12 (2011), 163–172.
59. [59] Xu, X., Zhao, C.X., Wang, L., et al. Increased CYP2J3 expression reduces insulin resistance in fructose-treated rats and db/db mice. Diabetes 59 (2010), 997–1005.
60. [60] Luria, A., Bettaieb, A., Xi, Y., et al. Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 9038–9043.
61. [61] Sodhi, K., Inoue, K., Gotlinger, K.H., et al. Epoxyeicosatrienoic acid agonist rescues the metabolic syndrome phenotype of HO-2-null mice. J. Pharmacol. Exp. Ther. 331 (2009), 906–916.
62. [62] Sodhi, K., Puri, N., Inoue, K., et al. EET agonist prevents adiposity and vascular dysfunction in rats fed a high fat diet via a decrease in Bach 1 and an increase in HO-1 levels. Prostaglandins Other Lipid Mediat. 98 (2012), 133–142.
63. [63] Ohtoshi, K., Kaneto, H., Node, K., et al. Association of soluble epoxide hydrolase gene polymorphism with insulin resistance in type 2 diabetic patients. Biochem. Biophys. Res. Commun. 331 (2005), 347–350.
64. [64] Surendiran, A., Pradhan, S.C., Agrawal, A., et al. Influence of CYP2C9 gene polymorphisms on response to glibenclamide in type 2 diabetes mellitus patients. Eur. J. Clin. Pharmacol. 67 (2011), 797–801.
65. [65] Zhou, K., Donnelly, L., Burch, L., et al. Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study. Clin. Pharmacol. Ther. 87 (2010), 52–56.
66. [66] Ragia, G., Petridis, I., Tavridou, A., et al. Presence of CYP2C9*3 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics 10 (2009), 1781–1787.
67. [67] Wang, C.P., Hung, W.C., Yu, T.H., et al. Genetic variation in the G-50T polymorphism of the cytochrome P450 epoxygenase CYP2J2 gene and the risk of younger onset type 2 diabetes among Chinese population: potential interaction with body mass index and family history. Exp. Clin. Endocrinol. Diabetes 118 (2010), 346–352.
68. [68] Chen, D., Whitcomb, R., MacIntyre, E., et al. Pharmacokinetics and pharmacodynamics of AR9281, an inhibitor of soluble epoxide hydrolase, in single- and multiple-dose studies in healthy human subjects. J. Clin. Pharmacol. 52 (2012), 319–328.
69. [69] Liu, J.Y., Park, S.H., Morisseau, C., et al. Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo. Mol. Cancer Ther. 8 (2009), 2193–2203.
70. [70] Hall, J.E., The kidney, hypertension, and obesity. Hypertension 41 (2003), 625–633.
71. [71] Wang, M.H., Smith, A., Zhou, Y., et al. Downregulation of renal CYP-derived eicosanoid synthesis in rats with diet-induced hypertension. Hypertension 42 (2003), 594–599.
72. [72] Dobrian, A.D., Davies, M.J., Prewitt, R.L., et al. Development of hypertension in a rat model of diet-induced obesity. Hypertension 35 (2000), 1009–1015.
73. [73] Zhou, Y., Lin, S., Chang, H.H., Du, J., et al. Gender differences of renal CYP-derived eicosanoid synthesis in rats fed a high-fat diet. Am. J. Hypertens. 18 (2005), 530–537.
74. [74] Theken, K.N., Schuck, R.N., Edin, M.L., et al. Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease. Atherosclerosis 222 (2012), 530–536.
75. [75] Halcox, J.P., Narayanan, S., Cramer-Joyce, L., et al. Characterization of endothelium-derived hyperpolarizing factor in the human forearm microcirculation. Am. J. Physiol. 280 (2001), H2470–H2477.
76. [76] Versara, D., Cipriano, A., Virdis, A., et al. Involvement of cytochrome P450 2C9 pathway sensitive to sulfaphenazole in the endothelium-dependent vasodilation of essential hypertensive patients. Hypertension, 44, 2005, P131 (10-9-2004).
77. [77] Zhang, L.N., Vincelette, J., Chen, D., et al. Inhibition of soluble epoxide hydrolase attenuates endothelial dysfunction in animal models of diabetes, obesity and hypertension. Eur. J. Pharmacol. 654 (2011), 68–74.
78. [78] Zhao, X., Dey, A., Romanko, O.P., et al. Decreased epoxygenase and increased epoxide hydrolase expression in the mesenteric artery of obese Zucker rats. Am. J. Physiol. 288 (2005), R188–R196.
79. [79] Abraham, N.G., Sodhi, K., Silvis, A.M., et al. CYP2J2 targeting to endothelial cells attenuates adiposity and vascular dysfunction in mice fed a high-fat diet by reprogramming adipocyte phenotype. Hypertension 64 (2014), 1352–1361.
80. [80] Roche, C., Besnier, M., Cassel, R., et al. Soluble epoxide hydrolase inhibition improves coronary endothelial function and prevents the development of cardiac alterations in obese insulin-resistant mice. Am. J. Physiol. 308 (2015), H1020–H1029.
81. [81] Ma, B., Xiong, X., Chen, C., et al. Cardiac-specific overexpression of CYP2J2 attenuates diabetic cardiomyopathy in male streptozotocin-induced diabetic mice. Endocrinology 154 (2013), 2843–2856.
82. [82] Dewey, S., Lai, X., Witzmann, F.A., et al. Proteomic analysis of hearts from Akita mice suggests that increases in soluble epoxide hydrolase and antioxidative programming are key changes in early stages of diabetic cardiomyopathy. J. Proteome Res. 12 (2013), 3920–3933.